| Identification | Back Directory | [Name]
2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-ethyl-4-oxo-2-buten-1-yl]tetrahydro-, hydrochloride (1:1) | [CAS]
1613458-78-8 | [Synonyms]
4-amino-N-[(3S,4E)-6-(2,3-dihydro-1H-indol-1-yl)-6-oxohex-4-en-3-yl]tetrahydropyran-4-carboxamide hydrochloride
2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-ethyl-4-oxo-2-buten-1-yl]tetrahydro-, hydrochloride (1:1) | [Molecular Formula]
C20H28ClN3O3 | [MOL File]
1613458-78-8.mol | [Molecular Weight]
393.91 |
| Hazard Information | Back Directory | [Uses]
GSK-2793660 is an orally active and irreversible inhibitor of Cathepsin C (CTSC). GSK-2793660 can be used for the research of bronchiectasis[1][2]. | [in vivo]
GSK-2793660 is a cathepsin C (also known as dipeptidyl peptidase I enzyme) inhibitor for the reaearch of cystic fibrosis, non-cystic fibrosis bronchiectasis, anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and bronchiectasis[1]. | [IC 50]
Cathepsin C | [References]
[1] Szcze?niak P, et al. The Synthesis of α,α-Disubstituted α-Amino Acids via Ichikawa Rearrangement. J Org Chem. 2016;81(3):1057-1074. DOI:10.1021/acs.joc.5b02628
[2] Miller BE, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017;83(12):2813-2820. DOI:10.1111/bcp.13398 |
|
| Company Name: |
Abosyn
|
| Tel: |
0512-69561983 13914027025 |
| Website: |
abosyn.cn/ |
|